Agendia, Illumina partner on genomic testing for breast cancer

By staff writers

January 11, 2022 -- Precision oncology firm Agendia has announced a multiyear partnership with Illumina to co-develop IVD tests for oncology testing. The companies aim to bring improved insights to patients with breast cancer, Agendia said.

Illumina and Agendia plan to develop new tests to enhance the care of breast cancer patients by using the Illumina MiSeqDx sequencing platform to expand the range of gene panels available for solid tumor analysis, Agendia said.

Agendia believes that its MammaPrint test could be the first decentralized next-generation sequencing-based breast cancer recurrence risk test cleared by the U.S. Food and Drug Administration (FDA). The test is already cleared by the FDA and offered through Agendia's central laboratory.

Illumina, Merck partner on HRD test
Illumina and Merck have agreed to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency...
Illumina completes Grail deal, despite lack of European approval
Illumina has completed its acquisition of cancer diagnostics developer Grail, almost a year after announcing the deal. Illumina said it would run Grail...
Agendia touts MammaPrint clinical results
Agendia is highlighting research shared at the virtual 2021 American Society of Clinical Oncology meeting that shows its MammaPrint 70-gene signature...
Illumina donates $60M in NGS tools to build genomic network
Illumina is donating $60 million in next-generation sequencing (NGS) platforms, reagents, and support to create a comprehensive pathogen genomic...
Agendia, Paige partner to better breast cancer treatment
Genetic testing company Agendia and artificial intelligence pathology company Paige have partnered to improve planning for breast cancer treatment, with...

Copyright © 2022

Last Updated ka 1/11/2022 5:00:12 PM